Oruka Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Oruka Therapeutics, Inc. (ORKA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $10.05 per share for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2024-08-01
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $17.45, a 401.44% increase year-over-year.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.48, a 12.99% increase year-over-year.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $3.08, a 95.74% decline year-over-year.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2021-03-31 was $72.33, a 87.78% decline year-over-year.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $11.68, a 146.41% increase from fiscal 2022.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $4.74, a 62.71% decline from fiscal 2021.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2021 was $12.71, a 97.92% decline from fiscal 2020.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2020 was $610.46, a 143.83% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | $10.05 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | $17.45 10-Q · filed 2024-04-25 | ||||
| 2023-12-31 | $11.68 10-K · filed 2024-02-01 | ||||
| 2023-09-30 | $11.52 10-Q · filed 2023-10-18 | ||||
| 2023-06-30 | $5.80 10-Q · filed 2023-07-21 | ||||
| 2023-03-31 | $3.48 10-Q · filed 2023-04-24 | ||||
| 2022-12-31 | $4.74 10-K · filed 2024-02-01 | ||||
| 2022-09-30 | $3.31 10-Q · filed 2022-10-28 | ||||
| 2022-06-30 | $3.08 10-Q · filed 2022-08-02 | ||||
| 2022-03-31 | $3.08 10-Q · filed 2022-05-02 | ||||
| 2021-12-31 | $12.71 10-K · filed 2023-02-24 | ||||
| 2021-09-30 | $12.71 10-Q · filed 2021-11-02 | ||||
| 2021-06-30 | $10.84 10-Q · filed 2021-08-04 | ||||
| 2021-03-31 | $72.33 10-Q · filed 2021-05-11 | ||||
| 2020-12-31 | $610.46 10-K · filed 2022-03-14 | ||||
| 2020-09-30 | $610.46 10-Q · filed 2020-11-02 | ||||
| 2020-06-30 | $591.88 10-Q · filed 2020-08-05 | ||||
| 2020-03-31 | $591.88 10-Q · filed 2020-05-06 | ||||
| 2019-12-31 | $250.36 10-K · filed 2021-03-18 | ||||
| 2019-09-30 | $607.30 10-Q · filed 2019-11-06 | ||||
| 2019-06-30 | $724.80 10-Q · filed 2019-08-01 | ||||
| 2019-03-31 | $1579.97 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | $169.17 10-K · filed 2020-02-18 | $9.51 10-K · filed 2019-02-27 | |||
| 2018-09-30 | $8.37 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | $4.58 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $7.54 10-Q · filed 2018-05-08 | ||||
| 2017-12-31 | $3.05 10-K · filed 2019-02-27 | ||||
| 2017-09-30 | $3.38 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $3.38 10-Q · filed 2017-08-03 | ||||
| 2017-03-31 | $3.34 10-Q · filed 2017-05-15 | ||||
| 2016-12-31 | $28.70 10-K · filed 2018-03-22 | ||||
| 2016-09-30 | $28.39 10-Q · filed 2016-11-14 | ||||
| 2016-06-30 | $28.39 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | $28.94 10-Q · filed 2016-05-11 | ||||
| 2015-12-31 | $18.45 10-K · filed 2017-03-21 | ||||
| 2015-09-30 | $21.72 10-Q · filed 2015-11-12 | ||||
| 2015-06-30 | $1.69 10-Q · filed 2015-08-11 | ||||
| 2015-03-31 | $0.36 10-Q · filed 2015-05-12 | ||||
| 2014-12-31 | $867.70 10-K · filed 2016-03-17 | $140.67 10-K · filed 2015-03-19 | |||
| 2014-09-30 | $140.67 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | $140.67 10-Q · filed 2014-08-13 | ||||
| 2014-03-31 | $1908.00 10-Q · filed 2014-05-13 | ||||
| 2013-12-31 | $11.62 10-K · filed 2015-03-19 | ||||
| 2013-09-30 | $11.07 10-Q · filed 2013-11-13 | ||||
| 2013-06-30 | $23.35 10-Q · filed 2013-08-13 | ||||
| 2013-03-31 | $16.53 10-Q · filed 2013-05-13 | ||||
| 2012-12-31 | $27.96 10-K · filed 2014-03-20 | ||||
| 2012-09-30 | $5.82 10-Q · filed 2012-11-13 | ||||
| 2012-06-30 | $4.91 10-Q · filed 2012-08-13 | ||||
| 2011-12-31 | $664.86 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |